Blog

When to Conduct Hepatic Impairment Studies and When Modeling May be Enough

How to decide if a hepatic impairment study is required, choose the right study design,…

CertaraJuly 13, 2026

Conference

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

CertaraJuly 9, 2026

Webinar

Integrated mechanistic modeling approaches in oncology drug development

CertaraJuly 8, 2026

Blog

Dosimetry tells you the dose. It doesn’t tell you the decision.

Learn why absorbed dose data alone isn't enough for radiopharmaceutical dose optimization, and how BED,…

CertaraJuly 7, 2026

Webinar

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

CertaraJuly 1, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

CertaraJune 26, 2026

Poster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

CertaraJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Model Informed Drug Development

When to Conduct Hepatic Impairment Studies and When Modeling May be Enough

ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Integrated mechanistic modeling approaches in oncology drug development

Dosimetry tells you the dose. It doesn’t tell you the decision.

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

Enhancing clinical trials with real-world evidence in pregnancy research

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Newsletter sign up

Quick links

Solutions

Contact